FDA extends motavizumab review

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA issued a new PDUFA date of Aug. 27 for a BLA from the company's MedImmune LLC unit for motavizumab to prevent serious infection with respiratory syncytial ...